Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
231
Employees231
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
231
Employees231

CAPR Key Statistics

Market cap
1.82B
Market cap1.82B
Price-Earnings ratio
-13.97
Price-Earnings ratio-13.97
Dividend yield
Dividend yield
Average volume
1.29M
Average volume1.29M
High today
$32.43
High today$32.43
Low today
$30.50
Low today$30.50
Open price
$31.55
Open price$31.55
Volume
1.06M
Volume1.06M
52 Week high
$40.37
52 Week high$40.37
52 Week low
$4.30
52 Week low$4.30

Stock Snapshot

As of today, Capricor(CAPR) shares are valued at $31.46. The company's market cap stands at 1.82B, with a P/E ratio of -13.97.

On 2026-05-13, Capricor(CAPR) stock traded between a low of $30.50 and a high of $32.43. Shares are currently priced at $31.46, which is +3.1% above the low and -3.0% below the high.

The Capricor(CAPR)'s current trading volume is 1.06M, compared to an average daily volume of 1.29M.

During the past year, Capricor(CAPR) stock moved between $4.30 at its lowest and $40.37 at its peak.

During the past year, Capricor(CAPR) stock moved between $4.30 at its lowest and $40.37 at its peak.

CAPR News

Nasdaq 3d
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story

Key Points 25,000 common shares were sold for a total transaction value of ~$793,000 on May 1, 2026, at a weighted average price of $31.70 per share. The tran...

Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
TipRanks 5d
Capricor files suit against NS Pharma over Deramiocel distribution deal

Capricor Therapeutics (CAPR) announced that it has filed a lawsuit against Nippon Shinyaku (NPNKF) and its U.S. subsidiary, NS Pharma, over the parties’ U.S. di...

Benzinga 5d
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

The biotechnology company said the dispute centers on pricing terms in the commercialization and distribution agreement tied to Deramiocel, an investigational c...

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More CAPR News

TipRanks 5d
Capricor Sues NS Pharma Over Deramiocel U.S. Rights

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.